Bioiberica presented a study on the efficacy of Entero-Chronic at the ACVIM conference

This year’s ACVIM Conference, which was attended by some of the most noted international specialists in internal veterinarian medicine, was held on 3-6 June in Indianapolis (Indiana, USA). Sergi Segarra, head of the R&D department at Bioiberica’s Veterinary Division, presented the latest study demonstrating the efficacy of Entero-Chronic®: Effects of an Oral Supplement Based on Chondroitin Sulfate, Resistant Starch, and Prebiotics in Dogs with IBD (Inflammatory Bowel Disease).

Canine IBD is a chronic disease of unknown etiology. Although there are currently available several therapeutic options to improve its symptoms, the regular use of the most common treatments often causes secondary effects.

For the study, scientists recruited a group of IBD dogs. These were divided into two groups: the first was administered Entero-Chronic® for six months, whereas the second was administered a placebo. Both groups were given a hypoallergenic diet and had excellent tolerance of the treatments received, without any secondary effects being presented during the monitoring period. However, dogs on an Entero-Chronic® treatment experienced a faster and most marked clinical improvement than the group receiving placebo. They also had histopathology improvements, a lower number of relapses and lower inflammation and oxidative stress in blood, as well as an increase in their bowel absorption capacity. 

Therefore, the results seem to confirm the benefits of Entero-Chronic® treatment for IBD dogs, as well as its good safety profile.

Furthermore, the study’s authors highlighted that the anti inflammatory action of chondroitin sulfate is an especially relevant finding for the research on treatment of IBD in humans (Crohn disease, ulcerative colitis), which has characteristics in common with canine IBD.